PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22227463-1	2012	On the basis of the previous lead N-4-t-butylbenzyl 2-(3-fluoro-4-methylsulfonylaminophenyl) propanamide (3) as a potent TRPV1 antagonist, structure-activity relationships for the B (propanamide part) and C-region (4-t-butylbenzyl part) have been investigated for rTRPV1 in CHO cells.	propionamide	93-104	LOW QUALITY PROTEIN: transient receptor potential cation channel subfamily V member 1	Cricetulus griseus	121-126
18805694-0	2008	Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators.	propionamide	57-69	androgen receptor	Homo sapiens	80-97
21867721-0	2011	Facile radiosynthesis of new carbon-11-labeled propanamide derivatives as selective androgen receptor modulator (SARM) radioligands for prostate cancer imaging.	propionamide	47-58	sterile alpha and TIR motif containing 1	Homo sapiens	74-111
21867721-0	2011	Facile radiosynthesis of new carbon-11-labeled propanamide derivatives as selective androgen receptor modulator (SARM) radioligands for prostate cancer imaging.	propionamide	47-58	sterile alpha and TIR motif containing 1	Homo sapiens	113-117
21867721-2	2011	New carbon-11-labeled propanamide derivatives were first designed and synthesized as selective androgen receptor modulator (SARM) radioligands for prostate cancer imaging using the biomedical imaging technique positron emission tomography (PET).	propionamide	22-33	androgen receptor	Homo sapiens	95-112
21867721-2	2011	New carbon-11-labeled propanamide derivatives were first designed and synthesized as selective androgen receptor modulator (SARM) radioligands for prostate cancer imaging using the biomedical imaging technique positron emission tomography (PET).	propionamide	22-33	sterile alpha and TIR motif containing 1	Homo sapiens	124-128
16381665-0	2006	Pharmacokinetics and metabolism of a selective androgen receptor modulator in rats: implication of molecular properties and intensive metabolic profile to investigate ideal pharmacokinetic characteristics of a propanamide in preclinical study.	propionamide	210-221	androgen receptor	Rattus norvegicus	47-64
1092343-3	1975	However, desGly-10-LH-RH-2,2,3,3,3-pentafluoropropylamide was only slightly more active than LH-RH and considerably less active than the corresponding propylamide analog.	propionamide	46-57	gonadotropin releasing hormone 1	Rattus norvegicus	19-24
13678149-8	2003	The original method yielded both CAM and propionicamide (PAM;-S-CH2CH2CONH2) derivatives.	propionamide	41-55	peptidylglycine alpha-amidating monooxygenase	Homo sapiens	57-60
9357057-2	1997	In this study we have shown that although bombesin cannot stimulate ACTH secretion alone, it potentiates release by ovine CRF, an effect blocked by the GRP receptor antagonist D-Tyr6bombesin (6-13) propylamide.	propionamide	198-209	gastrin releasing peptide	Homo sapiens	42-50
9357057-2	1997	In this study we have shown that although bombesin cannot stimulate ACTH secretion alone, it potentiates release by ovine CRF, an effect blocked by the GRP receptor antagonist D-Tyr6bombesin (6-13) propylamide.	propionamide	198-209	gastrin releasing peptide	Homo sapiens	152-155
7510340-5	1994	Inhibitory activity against EGF receptor tyrosine kinase was chain-length dependent, with the propanamides being the most effective.	propionamide	94-106	epidermal growth factor	Homo sapiens	28-31
7510340-5	1994	Inhibitory activity against EGF receptor tyrosine kinase was chain-length dependent, with the propanamides being the most effective.	propionamide	94-106	ret proto-oncogene	Homo sapiens	32-56
1320123-5	1992	The introduction of a propionamide moiety at C-3 enhanced activity by 1 order of magnitude; N-[4-[[6-(cyclopentylacetamido)-3-[2-(N- methylcarbamoyl)ethyl]indol-1-yl]methyl]-3-methoxy- benzoyl]benzenesulfonamide (15c) has a pKB of 10.7 at the LTD4 receptor on guinea pig trachea.	propionamide	22-34	cysteinyl leukotriene receptor 1	Cavia porcellus	243-256
1320123-8	1992	In both series this potency loss could be regained by the incorporation of a propionamide substituent at either C-3 or N-1, respectively.	propionamide	77-89	complement C3	Cavia porcellus	112-115
34913596-3	2022	Herein, Ru/Nb2 O5 catalyst is demonstrated to be highly efficient and stable for the selective hydrogenation of propionamide to propylamine (as a model reaction), with up to 91.4% yield of propylamine under relatively mild conditions.	propionamide	112-124	contactin 5	Homo sapiens	11-14
10083976-2	1999	Synthesis of N-2,3 or 4-pyridinyl-(indol-3-yl) acetamides and propionamides 3-10 was achieved starting from the corresponding Ph3P/BrCCl3 or DCC-activated acids.	propionamide	62-75	deleted in colorectal carcinoma	Mus musculus	141-144
1320123-5	1992	The introduction of a propionamide moiety at C-3 enhanced activity by 1 order of magnitude; N-[4-[[6-(cyclopentylacetamido)-3-[2-(N- methylcarbamoyl)ethyl]indol-1-yl]methyl]-3-methoxy- benzoyl]benzenesulfonamide (15c) has a pKB of 10.7 at the LTD4 receptor on guinea pig trachea.	propionamide	22-34	complement C3	Cavia porcellus	45-48
34273488-0	2021	2-(Halogenated Phenyl) Acetamides and Propanamides as Potent TRPV1 Antagonists.	propionamide	38-50	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	61-66
34273488-1	2021	A series consisting of 117 2-(halogenated phenyl) acetamide and propanamide analogs were investigated as TRPV1 antagonists.	propionamide	64-75	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	105-110
34269581-1	2021	A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism.	propionamide	12-23	androgen receptor	Homo sapiens	113-130
34269581-1	2021	A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism.	propionamide	12-23	androgen receptor	Homo sapiens	194-211
34269581-1	2021	A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism.	propionamide	12-23	androgen receptor	Homo sapiens	213-215
30078610-0	2018	4-Aminophenyl acetamides and propanamides as potent transient receptor potential vanilloid 1 (TRPV1) ligands.	propionamide	29-41	transient receptor potential cation channel subfamily V member 1	Homo sapiens	52-92
29775949-0	2018	Design and synthesis of some new carboxamide and propanamide derivatives bearing phenylpyridazine as a core ring and the investigation of their inhibitory potential on in-vitro acetylcholinesterase and butyrylcholinesterase.	propionamide	49-60	acetylcholinesterase (Cartwright blood group)	Homo sapiens	177-197
30078610-0	2018	4-Aminophenyl acetamides and propanamides as potent transient receptor potential vanilloid 1 (TRPV1) ligands.	propionamide	29-41	transient receptor potential cation channel subfamily V member 1	Homo sapiens	94-99
30078610-2	2018	The analysis of the structure-activity relationship indicated that 2-(3,5-dihalo 4-aminophenyl)acetamide analogues displayed excellent antagonism of hTRPV1 activation by capsaicin and showed improved potency compared to the corresponding propanamides.	propionamide	238-250	transient receptor potential cation channel subfamily V member 1	Homo sapiens	149-155